The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: A modelling study

Benjamin Bowe  
*Saint Louis University*

Elena Artimovich  
*VA Saint Louis Health Care System*

Yan Xie  
*Saint Louis University*

Yan Yan  
*Washington University School of Medicine in St. Louis*

Miao Cai  
*Saint Louis University*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs) 

Please let us know how this document benefits you.

**Recommended Citation**

Bowe, Benjamin; Artimovich, Elena; Xie, Yan; Yan, Yan; Cai, Miao; and Al-Aly, Ziyad, "The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: A modelling study." BMJ Global Health. 5, 3. e002063 (2020).  
https://digitalcommons.wustl.edu/open_access_pubs/11104

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study

Benjamin Bowe,1,2 Elena Artimovich,1 Yan Xie,1,2 Yan Yan,1,3 Miao Cai,1,2 Ziyad Al-Aly 1,4,5,6

ABSTRACT

Introduction We aimed to integrate all available epidemiological evidence to characterise an exposure–response model of ambient fine particulate matter (PM2.5) and the risk of chronic kidney disease (CKD) across the spectrum of PM2.5 concentrations experienced by humans. We then estimated the global and national burden of CKD attributable to PM2.5.

Methods We collected data from prior studies on the association of PM2.5 with CKD and used an integrative meta-regression approach to build non-linear exposure–response models of the risk of CKD associated with PM2.5 exposure. We then estimated the 2017 global and national incidence, prevalence, disability-adjusted life-years (DALYs) and deaths due to CKD attributable to PM2.5 in 194 countries and territories. Burden estimates were generated by linkage of risk estimates to Global Burden of Disease study datasets.

Results The exposure–response function exhibited evidence of an increase in risk with increasing PM2.5 concentrations, where the rate of risk increase gradually attenuated at higher PM2.5 concentrations. Globally, in 2017, there were 3 284 358.2 (95% UI 2 800 710.5 to 3 747 046.1) prevalent cases of CKD attributable to PM2.5, 6 593 134.6 (5 705 180.4 to 7 479 818.4) DALYs and 211 019.2 (184 292.5 to 236 520.4) deaths due to CKD attributable to PM2.5. The burden was disproportionately borne by low income and lower middle income countries and exhibited substantial geographic variability, even among countries with similar levels of sociodemographic development. Globally, 72.8% of prevalent cases of CKD attributable to PM2.5 and 74.2% of DALYs due to CKD attributable to PM2.5 were due to concentrations above 10 μg/m³, the WHO air quality guidelines.

Conclusion The global burden of CKD attributable to PM2.5 is substantial, varies by geography and is disproportionately borne by disadvantaged countries. Most of the burden is associated with PM2.5 levels above the WHO guidelines, suggesting that achieving those targets may yield reduction in CKD burden.

INTRODUCTION

A number of large epidemiological studies have described the relationship between ambient fine particulate matter of <2.5 μm in aerodynamic diameter (PM2.5) and chronic kidney disease (CKD).1–3 Several experimental studies in mice and rats suggest that inhalation of PM2.5 promotes oxidative stress, inflammation and DNA damage in kidney tissue and leads to structural chronic kidney injury manifested by glomerulosclerosis, mesangial expansion, tubular atrophy and vascular damage, providing a plausible biological mechanism for the injurious effect of PM2.5 on the kidney.4–10 We recently described global and national estimates of CKD burden of PM2.5.
attributable to PM$_{2.5}$ pollution based on an exposure–response function derived from a single US cohort with a narrow range of PM$_{2.5}$ exposure that may limit generalisability of these estimates. A significant knowledge gap exists in that the PM$_{2.5}$–CKD exposure–response function across the concentrations of PM$_{2.5}$ experienced by humans worldwide has not been characterised. Characterisation of an exposure–response function that integrates all available evidence will allow for more accurate estimation of CKD burden for a geographic area or a population group with well-defined exposure estimates. Estimation of burden of kidney disease will also contribute to the global discussion about the relationship between environmental air pollution and non-communicable diseases in general and specifically on the contribution of air pollution to the global and national burden of CKD.

In this work, we systematically searched all published reports on the relationship between PM$_{2.5}$ and CKD and used advanced methodologies to build and characterise an integrated non-linear exposure response model; we then generated estimates of the global and national burden of CKD attributable to PM$_{2.5}$ air pollution and estimated the burden attributable to levels of PM$_{2.5}$ exceeding the WHO PM$_{2.5}$ air quality standards.

**METHODS**

**Characterisation of the risk of CKD associated with PM$_{2.5}$**

To estimate the magnitude of the risk of CKD associated with PM$_{2.5}$ exposure across the spectrum of concentrations experienced by humans, we curated all available evidence for use in an integrative meta-regression approach. Prior work in the quantification of the global health risk of PM$_{2.5}$ has, for diseases with limited evidence across the entire PM$_{2.5}$ exposure range, additionally incorporated outcome associations with secondhand smoke, household air pollution and active smoking exposures as a means of calibration of exposure–response curve morphology at higher—otherwise understudied—PM$_{2.5}$ exposure values. However, recent literature has suggested that this approach may result in underestimation of risk, and therefore may not be the most optimal strategy to characterise risk if a preponderance of studies is available. Here, due to a potentially limited pool of PM$_{2.5}$ and CKD studies, we chose to estimate the non-linear exposure–response with methodological considerations based on both the integrated exposure–response (IER) method, which incorporates proxy exposures into estimation, and global exposure morality model (GEMM) method, which relies exclusively on PM$_{2.5}$ data, allowing for comparison of results generated from data with and without inclusion of proxy exposures.

**Data curation**

The protocol followed for identification of available evidence for incorporation in integrative meta-regression is reported following recommend guidelines (online supplementary material). We searched PubMed, Web of Science and the Cochrane library for literature on cohort, case–control and cross-sectional studies of the association between CKD and PM$_{2.5}$. Searches were also conducted to identify studies on CKD and secondhand smoke, household air pollution and active smoking. Following the strategies outlined in our protocol, searches on 20 May 2019 resulted in identifying for potential inclusion 322 studies on ambient fine particulate matter air pollution, 301 on secondhand smoke and 535 on active smoking. We screened these studies based on the following inclusion criteria: published in a peer-reviewed journal; reported as having a cohort, case–control or cross-sectional study design; provided a measure of relative risk; available in English; and assessed risk of a kidney disease outcome. We initially selected a CKD outcome definition of an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m$^2$, as this is the most commonly used outcome definition in epidemiological studies of CKD. However, this definition was relaxed for proxy exposures, due to paucity of usable studies, to include kidney disease outcomes that have displayed relative risks similar in magnitude to incident eGFR <60 mL/min/1.73 m$^2$ in prior literature, such as eGFR decline ≥30% from baseline or incident stage 4 CKD. We furthermore excluded abstracts, as they lacked sufficient detail necessary for assessing risk of bias. Exposure type specific inclusion criteria included requiring studies on secondhand smoke to have a never-smoker comparison group and requiring studies on active smoking to have exposure definitions based on number cigarettes smoked per day. From selected studies, data were abstracted on study design, study outcome, range of exposure in the cohort, relative risk, relative risk uncertainty and aspects needed for risk of bias assessment. Studies risk of bias were scored using the Newcastle-Ottawa Scales for cohort and case–control studies and an adapted Newcastle–Ottawa scale for cross-sectional studies. These scales allow for assignment of a numeric score to each study as a means of assessing the potential of bias, where a higher score indicates less potential. Each study was independently scored by two study team members; any discrepancies in score were resolved by additional scoring by third member, where the majority score was taken. Scoring components that were tailored specifically for this study have been included in the protocol (supplement). Studies that scored less than 50% of the maximum score were considered to lack suitability for inclusion in the analyses. After applying eligibility criteria, we identified for inclusion in analyses six studies on PM$_{2.5}$ and CKD, one study on secondhand smoke and CKD and three studies on active smoking and CKD. Further details are provided in the supplement.

**Integrated non-linear exposure–response model**

To incorporate all relevant evidence on the association between PM$_{2.5}$ and CKD, we constructed integrated non-linear exposure–response models by adapting aspects of the GEMM approach by Burnett et al (2018) and the
IER approach by Burnett et al (2014). The GEMM uses state-of-the-art modelling techniques to model the shape of the association between PM_{2.5} and disease, leveraging study data that span the PM_{2.5} exposure range experienced by humans. A series of random effects models that pool the relative risk among studies are constructed, each assuming a different monotonic functional form, which are then ensembled to create a final estimate of the exposure–response. The relative risk for a model may be equated by $RR(z) = \exp(\theta \log(1 + \frac{z}{z_b}) \ast \omega(z))$, where $RR(z)$ is the relative risk of $z$ the exposure value, $\theta$ is the parameter estimate and $\omega(z)$ is a logistic weighting function $\omega(z) = \frac{1}{1+\exp\left(-\frac{z_a-z}{\tau}\right)} \ast \tau$ the range of pollutant concentrations and $\alpha, \mu$ and $\tau$ predefined parameters that affect the shape and curvature of estimated relations. A study’s $\log(RR)$ is then estimated as

$$\log (RR_{\omega}) = \theta \ast \left\{ \log \left(1 + \frac{z}{z_b}\right) \ast \left(1 + \exp \left(\frac{-\left(\frac{z_a-z}{\tau}\right)}{\tau}\right) \right) \right\}$$

where $z$ is the exposure for study $i$, $\omega$ is the $i^{th}$ exposure contrast, and hyperparameter values are set as $\alpha = (1.5, 3, 5, 7, 9)$, $\tau = (0.1, 0.2, 0.3, 0.4, 0.5, 0.6)$, and $\mu = (0\text{th}, 25\text{th}, 50\text{th}, 75\text{th} \text{ and } 100\text{th} \text{ percentile of the PM}_{2.5} \text{ distribution among all study cohorts})$. This results in a total 150 curves with monotonic morphology that include linear, log-linear, supralinear, sublinear and S shapes, where the choice of hyperparameters were made in line with prior literature. These models were used to construct an ensembled estimate (a weighted average), where models are weighted by model fit (better fit resulting in a higher weight), and errors are obtained through bootstrap. In defining $z_b$, and $z_o$ for PM_{2.5}, if risk across several categories of exposure were given, the median of each category was used, otherwise the 5th and 95th percentile (assuming a normal distribution) were used. Contrast values for secondhand smoke and active smoking were based on prior literature, where moderate or severe passive smoking and number of cigarettes per day were translated into PM_{2.5} mass inhaled concentration; $z_o$ of zero was used. For the distribution of $\mu$, we assumed an uniform distribution between the minimal and maximal PM_{2.5} values across the studies, as this allowed for a wide range of $\mu$ whose definition was not dominated by any one study with a large sample.

We employed four strategies in building the integrated non-linear exposure response model where we: (A) constructed the model using exclusively PM_{2.5} study data and deweighted cross-sectional studies; (B) constructed the model using PM_{2.5} study data only and did not deweight cross-sectional studies; (c) additionally included data from the proxy exposure studies based on IER methods and deweighted cross-sectional studies; and (D) additionally included data from proxy exposure studies and did not deweight cross-sectional studies. Data were weighted by sampling variance and risk of bias using the quality effects weighting method as proposed by Doi and Thalib. Models in cross-sectional studies were deweighted by setting the risk of bias scores to a minimal value (1), a reflection of their inability to establish temporality in exposure–response relations (and the resultant higher risk of bias). Random effects models were fit using the rma.mv routine in R with the options: method="REML", optimizer="optim". A compound symmetry (CS) covariance structure was specified; for models that incorporated proxy exposures, a structure of ("CS", "CS"), adding correlation at the study (nested within exposure type) and exposure type levels, was used. Two studies that were done in potentially the same cohort by the same group (Chen and Yang) were treated as being at the same study level. We additionally tested models specifying unstructured covariance; however, results were robust to this change, so the more parsimonious structure was kept. Resultant estimated risk are plotted for each of the four model versions, where a reference of 2.4 $\mu g/m^3$ is used, and all risk under 2.4 $\mu g/m^3$ was set to null, a reflection of burden estimation where a theoretical minimum risk exposure level (TMREL) of 2.4 $\mu g/m^3$ was used. As a means of visual presentation of fit for comparison of models with and without incorporation of proxy exposure data, we present for the best fit models (among the 150 models in the ensemble) a plot of the log ($RR_{\omega}$) along with plots of the studies data points. One thousand replications using a parametric bootstrap approach was used in obtaining the UI, where the 2.5th and 97.5th percentiles of the resultant distribution of the ensemble estimates are reported.

**Burden estimation**

Data on the global burden of CKD were obtained from the 2017 Global Burden of Disease (GBD) study, where the GBD estimates CKD stage 1–5. Briefly, deaths due to CKD are estimated using vital registration and verbal autopsy data sources, to which a garbage coding algorithm is applied in order to redistribute cause of death codes deemed implausible or possibly miscoded. Prevalence is estimated from a collation of studies on population level CKD rates and is augmented by population-based surveys of renal function and renal registry reports, including end-stage renal disease data from 109 countries and data on CKD stage 3–5 from 59 countries. These data were linked with 2017 PM_{2.5} global exposure estimates made available by GBD investigators. GBD estimates population weighted annual mean PM_{2.5} concentrations for each country and territory at an approximate 11 km $\times$ 11 km resolution from a synthesis of satellite-based estimates, chemical transport models and ground-level measurements from 9960 monitors from 108 countries; the population-weighted root mean squared error of the model was 8.11 $\mu g/m^3$. Using risk estimates from the integrated
We integrated all available evidence to build and characterise a non-linear exposure–response model of the relationship between PM$_{2.5}$ and risk of CKD; a flow chart of data curation and description of included studies are available in supplementary figure S1 and table 1.\textsuperscript{1 2 50–57} For potential inclusion in the meta-regression analyses, we identified six studies on PM$_{2.5}$, one study on second-hand smoke, and three studies on active smoking (online supplementary figure S1 and table 1), leading to a total of 30 data points, 15 of which were from PM$_{2.5}$ studies. No studies on household air pollution and risk of CKD were identified.

We considered four analytic approaches to building the integrated non-linear exposure–response function: (A) in analyses considering only studies on PM$_{2.5}$ and risk of CKD and where cross-sectional studies were deweighted (we designated this as the primary model), the exposure–response function exhibited evidence of an increase in risk with increasing PM$_{2.5}$ concentrations and the rate of risk increase gradually attenuated as PM$_{2.5}$ concentration increased (figure 1A); (B) analyses considering only studies on PM$_{2.5}$ and CKD and where cross-sectional studies were not deweighted produced consistent results (figure 1B); (C) analyses that also included active and passive smoking data as proxies of PM$_{2.5}$ exposure and where cross-sectional studies were deweighted yielded an exposure–response function that exhibited less risk for each given PM$_{2.5}$ concentration than when proxy exposures were not included (figure 1C); (D) analyses that also included active and passive smoking data as proxies of PM$_{2.5}$ exposure and where cross-sectional studies were not deweighted yielded results consistent with those in approach C (figure 1D). Plots of estimated risk versus study data points suggested that compared with models built using only PM$_{2.5}$ data, incorporation of proxy exposures resulted in underestimation of risk associated with PM$_{2.5}$ exposure (online supplementary figures S2A–D).

Global Burden of CKD attributable to PM$_{2.5}$ air pollution

We estimated the global burden of CKD attributable to air pollution using the PM$_{2.5}$ exposure–risk function where only studies on PM$_{2.5}$ and CKD were used and cross-sectional studies were deweighted (we designated this as the primary model and is depicted in figure 1A). At the global level, our estimates suggest that incidence of CKD attributable to PM$_{2.5}$ air pollution was 5 284 358.2 (95% UI 2 800 710.5 to 5 747 046.1) and prevalence was 122 409 460.2 (108 142 312.2 to 136 424 137.9). There were 6 593 134.6 (5 705 180.4 to 7 436 870.1) DALYs and 211 019.2 (184 292.5 to 236 520.4) deaths due to CKD attributable to PM$_{2.5}$ pollution. Rates per 100 000 and age-standardised rates per 100 000 for incidence, prevalence,
Table 1  Summary of studies incorporated in integrated non-linear exposure-response modelling

<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>Design</th>
<th>Sample size</th>
<th>Exposure source</th>
<th>Mean or median exposure range (SD or IQR)</th>
<th>CKD definition</th>
<th>Adjustments</th>
<th>Exposure contrast</th>
<th>RR (95% CI)</th>
<th>Risk of bias score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowe et al (2018)⁵⁷</td>
<td>Cohort</td>
<td>248273</td>
<td>PM₁₀</td>
<td>11.8 (5.0–22.1) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, race, sex, cancer, cardiovascular disease, chronic lung disease, diabetes mellitus, hyperlipidaemia, hypertension, baseline eGFR, BMI, smoking status, angiotensin-converting enzyme inhibitor / angiotensin receptor blocker use, county population density, number of outpatient eGFR measurements, number of hospitalisations and county percent in poverty.</td>
<td>Quartile 2 versus 1</td>
<td>1.02 (0.97 to 1.07)</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Chan et al (2018)⁵⁷</td>
<td>Cohort</td>
<td>100 629</td>
<td>PM₁₀</td>
<td>27.1 (5.8–49.6) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, educational level, smoking status, alcohol consumption, BMI, systolic BP, fasting glucose, total cholesterol, self-reported heart disease or stroke and baseline eGFR.</td>
<td>Quartile 2 versus 1</td>
<td>1.05 (0.95 to 1.15)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Yang et al (2018)⁵⁷</td>
<td>Cross-sectional</td>
<td>21 656</td>
<td>PM₁₀</td>
<td>26.6 (5.0) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, fasting glucose, cholesterol, hypertension, BMI, distance to major road, smoking status, alcohol consumption and education level.</td>
<td>Every 5.67µg/m³ increase</td>
<td>1.03 (0.97 to 1.09)</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Chen et al (2018)⁵⁷</td>
<td>Cross-sectional</td>
<td>8 497</td>
<td>PM₁₀</td>
<td>24.3 (12.8–48.2) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, BMI, education level, smoking status, alcohol consumption, hypertension and diabetes.</td>
<td>Every 4.1µg/m³ increase</td>
<td>1.01 (0.96 to 1.06)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Bragg-Gresham et al (2018)⁵⁷</td>
<td>Cross-sectional</td>
<td>1 164 057</td>
<td>PM₁₀</td>
<td>12.2 (6.1–16.8) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, race/ethnicity, hypertension, diabetes and urban/rural status.</td>
<td>Quartile 2 versus 1</td>
<td>1.02 (0.99 to 1.04)</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Weaver et al (2018)⁵⁷</td>
<td>Cross-sectional</td>
<td>5 090</td>
<td>PM₁₀</td>
<td>12.2 (0.6) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, BMI, education level, neighbourhood socioeconomic status, medical insurance, smoking status, physical activity, alcohol consumption, occupation, hyperlipidaemia, use of non-steroidal anti-inflammatory drugs, diuretic medication, statin medications, diabetes and hypertension and accounting for clustering by census tract.</td>
<td>Every 1µg/m³ increase</td>
<td>1.00 (0.82 to 1.22)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Jhee et al (2018)⁵⁷</td>
<td>Cohort</td>
<td>1 948</td>
<td>Passive smoking</td>
<td>– eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, BMI, systolic BP, history of hypertension, history of diabetes, alcohol status, education levels, income levels, marital status, haemoglobin and serum albumin.</td>
<td>Moderate secondhand smoke</td>
<td>1.58 (0.94 to 2.66)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Ejerblad et al (2004)⁵⁷</td>
<td>Case-Control</td>
<td>1 924</td>
<td>Active smoking</td>
<td>– eGFR &lt;60mL/min/1.73m²</td>
<td>Age, gender, education level, alcohol consumption, use of paracetamol and salicylates, pipe smoking, cigar smoking and snuff use.</td>
<td>1–10 cigarettes per day versus no smoking</td>
<td>0.89 (0.66 to 2.11)</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Hall et al (2016)⁵⁷</td>
<td>Cohort</td>
<td>3 648</td>
<td>Active smoking</td>
<td>– eGFR decline ≥30%</td>
<td>Age, sex, BMI, diabetes, hypertension, total cholesterol, education level, physical activity, prevalent cardiovascular disease and alcohol consumption.</td>
<td>1–19 cigarettes per day versus no smoking</td>
<td>1.75 (1.18 to 2.59)</td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

Continued
DALYs and death due to CKD attributable to PM$_{2.5}$ air pollution are provided in table 2.

In analyses using the exposure–response model where data from cross-sectional studies were not deweighted, the burden estimates closely matched those produced using the primary exposure–response model (where cross-sectional studies were deweighted), where the estimated absolute number of prevalent cases of CKD and DALYs due to CKD attributable to PM$_{2.5}$ were 88.8% and 89.1% of those of the primary model (table 2). In analyses using the exposure–response model, which also incorporated smoking data produced lower estimates of burden (table 2), estimating 33.5% and 33.7% as many prevalent cases of CKD and DALYs due to CKD attributable to PM$_{2.5}$ as the primary model; when cross-sectional studies were deweighted, the model estimated 31.5% and 31.8% as many prevalent cases of CKD and DALYs due to CKD attributable to PM$_{2.5}$ as the primary model, respectively.

**Burden of CKD attributable to PM$_{2.5}$ air pollution in 194 countries and territories**

We estimated the number, rate per 100 000 persons, and age-standardised rate per 100 000 persons for incidence, prevalence, DALYs and death due to CKD attributable to PM$_{2.5}$ air pollution for 194 countries and territories based on the primary model (online supplementary tables S1–S4). A map of the prevalent number of CKD attributable to PM$_{2.5}$ is presented in figure 2A. Maps of the age-standardised DALY rates, PAF, and age-standardised incidence, prevalence and death rates due to CKD attributable to PM$_{2.5}$ air pollution are provided in figure 2B and online supplementary figures S3–S6, respectively. Overall, there was substantial geographic variation in age-standardised burden, it was more pronounced in northern Africa, several countries in the Middle East, Southeast Asia, India and China.

**Burden of CKD and sociodemographic development**

Age-standardised rates for incidence, prevalence, DALYs and death due to CKD attributable to PM$_{2.5}$ pollution by World Bank income category are provide in table 3. The results suggest that the burden was higher in low income and lower middle income countries. Across the development spectrum, there was wide variation in estimated age-standardised DALY rates where several low and high SDI countries exhibited substantial deviation (both higher and lower) from expected burden based on their level of development (figure 3 and online supplementary table S5).

**Burden of CKD attributable to PM$_{2.5}$ levels above the WHO limit of 10 µg/m$^3$**

We then estimated the burden of CKD attributable to PM$_{2.5}$ concentrations above the WHO air quality standards (10 µg/m$^3$). Our results suggest that 72.8% of prevalent cases of CKD attributable to PM$_{2.5}$ and 74.2% of DALYs due to CKD attributable to PM$_{2.5}$ were due to concentrations above 10 µg/m$^3$ (table 4).
**Figure 1** Integed non-linear exposure–response curve of PM$_{2.5}$ and CKD. Curves are presented for the following strategies where: (A) only PM$_{2.5}$ study data were used and cross-sectional studies were deweighted; (B) only PM$_{2.5}$ study data were used; (C) data from studies on proxy exposure were additionally incorporated and cross-sectional studies were deweighted; and (D) data from studies on proxy exposure were additionally incorporated. Ninety-five per cent UI are presented as bands. A reference value of 2.4 µg/m$^3$ was used; all risk under the reference was set to unity. PM$_{2.5}$, ambient fine particulate matter.

**DISCUSSION**

In this work, we integrated all available evidence of the relationship between PM$_{2.5}$ and risk of CKD to build and characterise a non-linear exposure–response function to describe the risk of CKD across PM$_{2.5}$ concentrations experienced by humans. We estimated that in 2017, there were 3,284,358.2 (95% UI 2,800,710.5 to 3,747,046.1) incident and 122,409,460.2 (108,142,312.2 to 136,424,137.9) prevalent cases of CKD attributable to PM$_{2.5}$; and 6,593,134.6 (5,705,180.4 to 7,479,818.4) DALYs and 211,019.2 (184,292.5 to 236,520.4) deaths due to CKD attributable to PM$_{2.5}$ pollution. We produced estimates of CKD burden attributable to PM$_{2.5}$ pollution for 194 countries and territories and provided evidence that the burden is disproportionately borne by low income and lower middle income countries. Finally, we also show that 72.8% of the prevalent cases of CKD attributable to PM$_{2.5}$ air pollution and 74.2% of DALYs due to CKD attributable to PM$_{2.5}$ were associated with PM$_{2.5}$ levels above the WHO air quality standards.

We employed four strategies to build the non-linear exposure-risk function. We observed that deweighting cross-sectional studies did not appreciably influence the morphology of the risk–exposure model, nor did it result in substantially different estimates. However, the inclusion of active and passive smoking as proxies of PM$_{2.5}$ exposure resulted in a much smaller risk estimates and subsequently much lower burden estimates. These results are consistent with findings from Burnett and collaborators who noted that prior methodological approaches that incorporated active and passive smoke as proxy exposures of PM$_{2.5}$ resulted in significant underestimation of burden of death attributable to PM$_{2.5}$ pollution. More accurate estimation of CKD burden hinges on the availability of high-quality cohort studies representing the full spectrum of PM$_{2.5}$ exposure experienced by humans.

The WHO now officially recognises air pollution as a risk factor for non-communicable diseases, and there is increasing recognition that tackling air pollution is critical to addressing the rising tide of non-communicable diseases. Estimates of burden of non-communicable diseases attributable to air pollution are important to inform this effort, guide policy and inform future directions. In particular, as experimental evidence has accumulated over the past decade providing plausible biological mechanism to explain the effect of PM$_{2.5}$ on the kidney, and as large epidemiological studies linking PM$_{2.5}$ exposure with risk of kidney disease and death due to kidney disease became available, the need...
for a greater understanding and more accurate estimation of the burden of kidney disease attributable to PM$_{2.5}$ air pollution became more evident.\textsuperscript{16, 58} We previously provided estimates of CKD burden attributable to PM$_{2.5}$, which relied on a single large US cohort study.\textsuperscript{11} In this work, we integrated all available evidence and provided global and national estimates of burden of CKD attributable to PM$_{2.5}$ air pollution. The GBD study estimates that exposure to ambient particulate matter pollution is associated with 83 million DALY\textsubscript{s} \textsuperscript{59} likely underestimating—according to Burnett and colleagues\textsuperscript{18}—the global toll of death and disability attributable to air pollution.\textsuperscript{18} Our estimates suggest that CKD DALY\textsubscript{s} attributable to PM$_{2.5}$ air pollution were 6.5 million accounting for 7.8% of all DALY\textsubscript{s} attributable to ambient particulate matter pollution, reflecting the sizeable toll of this—so far largely ignored non-communicable disease.\textsuperscript{12-15, 59} As a significant body of epidemiological evidence on the effect of PM$_{2.5}$ on risk of kidney disease has accumulated over the past decade, it is important that PM$_{2.5}$ and CKD be considered for inclusion as a risk–outcome pair in future iterations of the comparative risk assessment framework of the GBD study. Such inclusion would allow for the derivation of estimates of the burden of CKD attributable to ambient PM$_{2.5}$ air pollution in the same computational modelling system considering other risks—including other environmental, occupational, behavioural and metabolic exposures\textsuperscript{48}—and other health outcomes (eg, under 5 mortality, which may be a competing risk for non-communicable diseases manifesting later in life), thus enabling more accurate comparative estimation of the burden of diseases attributable to PM$_{2.5}$ and the health burden of PM$_{2.5}$ relative to other risks. The GBD study framework also facilitates comparative evaluation of the health sequelae of PM$_{2.5}$ across geographies and over time.

We observed that estimates of the burden of CKD attributable to PM$_{2.5}$ air pollution exhibited substantial geographic variability and were higher in low and lower middle income countries—countries that are least equipped to deal with the untoward health consequences of pollution.\textsuperscript{11 35 60-62} Variations in PM$_{2.5}$-related CKD burden reflect the influence of differences in PM$_{2.5}$ exposure and differences in underlying CKD rates. Our estimated to expected ratio analyses based on SDI suggest that at both ends of the development gradients, PM$_{2.5}$ is a more potent risk factor for CKD than other forces (or drivers) of this burden and the potential—for so far unrealised—opportunities for reduction in burden.\textsuperscript{35 60}

Table 2

<table>
<thead>
<tr>
<th>Table 2 Estimates of the global burden of CKD attributable to PM$_{2.5}$ air pollution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modelling strategy</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

Rates are per 100 000 persons. CKD, chronic kidney disease; CS, cross-sectional; DALY, disability-adjusted life-year; PAF, population attributable fraction; PM$_{2.5}$, ambient fine particulate matter; UI, uncertainty interval.
Figure 2  Global burden of CKD attributable to PM$_{2.5}$ in 194 countries and territories. (A) Prevalence of CKD attributable to PM$_{2.5}$; (B) age-standardised disability-adjusted life-years (DALYs) rate (per 100 000) due to CKD attributable to PM$_{2.5}$. Countries are coloured by decile. CKD, chronic kidney disease; PM$_{2.5}$, ambient fine particulate matter; ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, Island; LCA, Saint Lucia; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
Our estimates suggest that the majority of the burden was attributable to PM$_{2.5}$ levels above the WHO air quality guidelines for annual mean PM$_{2.5}$ concentrations. The findings emphasise that for much of the world PM$_{2.5}$ levels remain too high and that further effort to reduce PM$_{2.5}$ concentrations—and meet the WHO air quality standards—may be associated with substantial reduction in burden of CKD worldwide.$^{11,16}$

This study has several limitations. While we integrated data from all available studies on PM$_{2.5}$ and CKD, our approach is inherently limited by the availability of data, and in particular, the paucity of large high-quality longitudinal studies of PM$_{2.5}$ and CKD from areas with very high PM$_{2.5}$ concentrations$^{3}$ and the lack of data for very low levels of PM$_{2.5}$ below the TMREL. There was also limited geographic diversity in the studies of PM$_{2.5}$ and CKD in that most were from western countries, few from East Asia, and none from Africa and the southern hemisphere. Our analyses did not consider potential heterogeneity of effect by population or regional characteristics, and we did not account for potential temporal or geospatial differences in composition and toxic content of PM$_{2.5}$. PM$_{2.5}$ is also associated with diabetes and hypertension, both known causal drivers of CKD; while the studies included in our metaregression analyses considered hypertension and diabetes as potential confounders, addressing the knowledge gap of whether to what extent the association between PM$_{2.5}$ and CKD is mediated by diabetes and hypertension may help further refine PM$_{2.5}$ burden attribution. Causal interpretation should be made with caution. In this work, we estimated the global and national burden of CKD attributable to PM$_{2.5}$ using GBD data for CKD burden, and PM$_{2.5}$ exposure estimates at the national level.$^{63}$ Our analyses do not include potential exposure to air pollutants other than PM$_{2.5}$ or to indoor air pollutants and do not provide further insight into PM$_{2.5}$ attributable burden at the subnational level. Our estimates of CKD attributable to PM$_{2.5}$ at the global and national levels reflect the influence of PM$_{2.5}$ levels across the globe and of demography and underlying CKD rates.

Strengths include the application of state-of-the-art methodologies to build an integrated exposure response function using data from several high-quality longitudinal cohort studies of PM$_{2.5}$ and CKD, and in particular, the incorporation of studies from China where PM$_{2.5}$ exposure is much higher than western countries. The functional form of our integrated exposure–response function and the resulting estimates of burden were not

---

**Table 3** Estimates of the population attributable fraction and age-standardised burden rate (per 100 000) of CKD attributable to PM$_{2.5}$ by World Bank income classification

<table>
<thead>
<tr>
<th>World Bank income classification</th>
<th>PAF (95% UI)</th>
<th>Incidence (95% UI)</th>
<th>Prevalence (95% UI)</th>
<th>DALY (95% UI)</th>
<th>Death (95% UI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low income</td>
<td>19.2 (17.6 to 20.8)</td>
<td>66.0 (56.8 to 74.8)</td>
<td>1925.2 (1699.1 to 2147.7)</td>
<td>127.0 (103.5 to 148.8)</td>
<td>4.8 (3.9 to 5.7)</td>
</tr>
<tr>
<td>Lower middle income</td>
<td>23.7 (22.0 to 25.5)</td>
<td>68.2 (58.8 to 77.3)</td>
<td>2350.2 (2087.8 to 2605.3)</td>
<td>149.1 (128.8 to 168.7)</td>
<td>5.4 (4.6 to 6.1)</td>
</tr>
<tr>
<td>Upper middle income</td>
<td>18.3 (16.8 to 19.8)</td>
<td>34.0 (28.9 to 38.6)</td>
<td>1498.7 (1324.2 to 1669.8)</td>
<td>66.2 (58.4 to 73.9)</td>
<td>2.5 (2.2 to 2.8)</td>
</tr>
<tr>
<td>High income</td>
<td>8.9 (8.0 to 9.7)</td>
<td>21.0 (17.6 to 24.1)</td>
<td>643.1 (561.8 to 722.0)</td>
<td>25.6 (21.3 to 29.7)</td>
<td>1.1 (0.9 to 1.3)</td>
</tr>
</tbody>
</table>

Estimates were generated using the integrated non-linear exposure response model using only PM$_{2.5}$ data where cross-sectional studies were deweighted.

CKD, chronic kidney disease; DALY, disability-adjusted life-year; PAF, population attributable fraction; PM$_{2.5}$, ambient fine particulate matter; UI, uncertainty interval.

---

**Figure 3** Map of the estimated to expected ratio of age-standardised disability-adjusted life-years (DALYs) due to CKD attributable to PM$_{2.5}$ based on level of sociodemographic development. Countries and territories are coloured by the estimated to expected ratio the age-standardised DALYs rate based on their sociodemographic index (SDI), where a ratio greater than one indicates greater than expected age-standardised DALYs, while a ratio less than one is less than expected. CKD, chronic kidney disease.
The estimated burden was unevenly distributed, and more disproportionately borne by low income and lower middle income countries. That nearly 3/4 of the burden is associated with PM$_{2.5}$ concentrations above the WHO air quality standards suggests potential unrealised opportunities for reduction in CKD burden.

**Table 4** Estimates of the global burden of CKD due to PM$_{2.5}$ above the WHO air quality guidelines for PM$_{2.5}$ (10 µg/m$^3$)

<table>
<thead>
<tr>
<th>Measure</th>
<th>PAF (95% UI)</th>
<th>Incidence (95% UI)</th>
<th>Prevalence (95% UI)</th>
<th>DALY (95% UI)</th>
<th>Death (95% UI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>14.7 (13.6 to 15.8)</td>
<td>2,338,578.5 (2,022,602.3 to 2,673,492.1)</td>
<td>89,111,428.8 (79,647,475.3 to 99,404,342.0)</td>
<td>4,894,988.1 (4,292,855.7 to 5,536,504.6)</td>
<td>152,388.2 (134,514.1 to 171,678.7)</td>
</tr>
<tr>
<td>Rate (per 100 000)</td>
<td>32.2 (27.8 to 36.8)</td>
<td>1230.3 (1099.6 to 1372.4)</td>
<td>67.4 (59.2 to 76.3)</td>
<td>2.1 (1.9 to 2.4)</td>
<td></td>
</tr>
<tr>
<td>Age-standardised rate (per 100 000)</td>
<td>37.3 (32.5 to 42.5)</td>
<td>1351.6 (1210.7 to 1504.9)</td>
<td>77.5 (67.8 to 87.9)</td>
<td>2.9 (2.5 to 3.3)</td>
<td></td>
</tr>
</tbody>
</table>

Estimates were generated using the integrated non-linear exposure response model using only PM$_{2.5}$ data where cross-sectional studies were deweighted.

**Map disclaimer** The depiction of boundaries on the map(s) in this article do not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. The map(s) are provided without any warranty of any kind, either express or implied.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Ethics approval** This research project was reviewed and approved by the Institutional Review Board of the VA Saint Louis Health Care System.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data is publically available. Data are available upon request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD** Ziyad Al-Aly http://orcid.org/0000-0002-2600-0434

**REFERENCES**


